protein solution at 11 mg/mL with 12% polyethylene glycol 20,000, 0.1 M sodium acetate pH 5.0, 0.1 M sodium/potassium tartrate, 0.02 M ammonium sulfate at 20 °C. Crystals were briefly soaked in mother liquor solution supplemented with 15% and then 30% glycerol before flash cooling in liquid nitrogen. Crystals of the NIH45-46-93TH057 complex (space group P2 1 2 1 2 1 , a = 69.1 Å, b = 70.5 Å, c = 217.7 Å; one molecule per asymmetric unit) were obtained upon mixing a protein solution at OD 280 =9.6 with 12% isopropanol, 10% polyethylene glycol 10,000, 0.1 M sodium citrate pH 5.0 at 20 °C. Complex crystals were cryo-cooled by covering the crystallization drops with paraffin oil to prevent evaporation and then adding an excess of 20% isopropanol, 5% glycerol, 10% polyethylene glycol, 0.1 M sodium citrate pH 5.0 to the drops prior to mounting and flash cooling the crystals in liquid nitrogen.
Data collection, structure solution and refinement
X-ray diffraction data were collected at the Stanford Synchrotron Radiation Lightsource (SSRL) beamline 12-2 using a Pilatus 6M pixel detector (Dectris). The data were indexed, integrated and scaled using XDS (35) . The Fab NIH45-46 structure was solved by molecular replacement using Phaser (36) and the V H V L and C H 1C L domains of the VRC01 Fab (PDB code 3NGB) as separate search models. The model was refined to 2.6 Å resolution using an iterative approach involving refinement using the Phenix crystallography package (37) and manually fitting models into electron density maps using Coot (38) . The final model (R work = 18.4%; R free = 23.8%) includes 3380 protein atoms, 125 water molecules and 37 ligand atoms, including N-Acetylglucosamine, glycerol and a sulfate ion (Table S1 ). 96.5%, 3.3% and 0.2% of the residues were in the favored, allowed and disallowed regions, respectively, of the Ramachandran plot. The first glutamine of the NIH45-46 heavy chain was modeled as 5-pyrrolidone-2-carboxylic acid.
A search model for solving the NIH45-46-93TH057 complex was created by superimposing the refined structure of the NIH45-46 Fab on the VRC01 Fab in the structure of VRC01-93TH057 (PDB code 3NGB). A molecular replacement solution was found as described above using separate search models for the V H V L domains of NIH45-46 complexed with 93TH057 and the C H 1C L domains of NIH45-46. (Table S1 ). The complex structure was refined to 2.45 Å resolution as described for the Fab structure. To reduce model bias, the CDRH3 of NIH45-46 was omitted from the model and then built into electron density maps after a few rounds of refinement. Formation of an introduced disulfide bond between residues 65 and 115 in 93TH057 gp120 was verified in a FoFc annealed omit electron density map contoured at 3.0 σ. The final model (R work = 20.7%; R free = 25.6%) includes 5989 protein atoms, 67 water molecules and 148 atoms of carbohydrates, citrate and chloride ions (Table S1) . 96.1%, 3.5% and 0.4% of the residues were in the favored, allowed and disallowed regions, respectively, of the Ramachandran plot. Disordered residues that were not included in the model were residues 1-2 of the NIH45-46 light chain, residues 133-136 and 219-221 of the heavy chain, and residues 302-308 (V3 substitution), residues 397-408 (a total of 6 residues from V4) and the 6x-His tag of 93TH057. The first glutamine of the NIH45-46 heavy chain was modeled as 5-pyrrolidone-2-carboxylic acid.
Buried surface areas were calculated using AreaIMol in CCP4 (39) and a 1.4 Å probe. Superimposition calculations were done and molecular representations were generated using PyMol (40) .
Surface Plasmon Resonance (SPR) measurements
The binding of gp120 core proteins to wild-type NIH45-46 Fab and to mutant (NIH45-46 G54W ) Fab was compared using a Biacore T100 instrument (GE Healthcare). Purified NIH45-46 and NIH45-46 G54W Fabs were immobilized at coupling densities of 500 resonance units (RU) or 1500 RU on a CM5 sensor chip (Biacore) in 10 mM acetate pH 5.0 using primary amine coupling chemistry as described in the Biacore manual. One of the four flow cells on each sensor chip was mock-coupled using buffer to serve as a blank. Experiments were performed at 25˚C in 20 mM HEPES, pH 7.0, 150 mM sodium chloride and 0.005% (v/v) surfactant P20, and the sensor chips were regenerated using 10 mM glycine, pH 2.5. gp120 core proteins were injected in a two-fold dilution series at concentrations ranging from 500 nM to 31.2 nM at a flow rate of 70 µL/min. After subtracting the signal from the mock-coupled flow cell, kinetic data were globally fit to a 1:1 binding model (Biacore evaluation software) to derive on-and off-rate constants, which were used to calculate affinities as
In vitro neutralization assays
A previously-described pseudovirus neutralization assay was used to compare the neutralization potencies of wild-type and mutant IgGs (41) . Neutralization assays were performed either by the Collaboration for AIDS Vaccine Discovery (CAVD) core neutralization facility (Fig 4A, Tables S5,  S6 ) or by our laboratory (Fig. S5C, S8 , Tables S2, S8) using the same protocol (41) . Briefly, pseudoviruses were generated in HEK293T cells by co-transfection of an Env-expressing vector and a replication-incompetent backbone plasmid. Neutralization was assessed by measuring the reduction in luciferase reporter gene expression in the presence of a potential inhibitor following a single round of pseudovirus infection in TZM-bl cells. Antibodies were pre-incubated with 250 infectious viral units in a three or four-fold dilution series for one hour at 37°C before adding 10,000 TZM-bl cells per well for a two-day incubation. Cells were then lysed and luciferase expression was measured using BrightGlo (Promega) and a Victor3 luminometer (PerkinElmer). Nonlinear regression analysis using the program Prism (GraphPad) was used to calculate the concentrations at which half-maximal inhibition was observed (IC 50 values) as described (42) . Samples were initially screened in duplicates. Reagents that showed enhanced activity were tested again as triplicates. Values for NIH45-46 and NIH45-46 G54W in Fig. S8A were obtained from three independent experiments. Similar IC 50 values were obtained in two independent neutralization experiments using different dilution series.
SUPPLEMENTARY DISCUSSION

Comparison of Tyr74 in NIH45-46 and VRC01
The conformation of heavy chain residue Tyr74, a FWR3 residue that was substituted during somatic hypermutation (16) , differs in the NIH45-46 and VRC01 structures. In NIH45-46-93TH057, the hydroxyl of Tyr74 NIH45-46 hydrogen bonds with the carbonyl oxygen of Leu122 gp120 in the bridging sheet (Fig. S4B) . The Tyr74 NIH45-46 sidechain adopts a similar orientation in the structure of unbound NIH45-46 despite a slight mainchain displacement (Fig. 1A) . By contrast, in VRC01-93TH057, the Tyr74 VRC01 sidechain is stabilized by Gly8 VRC01 of a crystallographic neighbor; rather than hydrogen bonding with Leu122 gp120 , it approaches Gly124 gp120 (part of a recombinant insert replacing V1-V2) (PDB code: 3NGB). As Tyr74 VRC01 probably occupies space filled by the V1-V2 stem, the conformation of Tyr74 observed in NIH45-46-93TH057 is likely favored when interacting with spike trimers on a virion, implying that VRC01, like NIH45-46, targets the bridging sheet as part of its binding surface on gp120. However, the Leu122 gp120 region of the bridging sheet was eliminated from the resurfaced RSC3 gp120 due to a truncation beginning at residue 121 (8) (Fig. S6) .
Comparison of NIH45-46 and VRC01 light chains
Contacts between the antibody light chain and gp120 are mostly conserved between the NIH45-46-93THO57 and VRC01-93THO57 structures with a notable exception: Ser28 NIH45-46 LC in CDRL1 replaces a solvent-exposed tyrosine (Tyr28 VRC01 LC ) that interacts with ordered N-linked carbohydrate attached to Asn276 93TH057 . By contrast, the Ser28 NIH45-46 LC sidechain does not contact gp120 carbohydrates; instead it faces away from gp120, hydrogen bonding with Arg64 NIH45-46 LC (FWR3) and creating a 2.7 Å displacement of the mainchain Cα atoms (Fig. S5A ). The Ser28 NIH45-46 LC -Arg64 NIH45-46 LC interaction is maintained in unbound NIH45-46 (Fig. S5B) . The position 28 substitution of serine for tyrosine largely accounts for the burial of more surface area in gp120's interaction with the VRC01 versus NIH45-46 light chain (681 Å 2 versus 395 Å 2 total buried surface area; 314 Å 2 versus 203 Å 2 buried surface area on the light chain) ( Table S4 ). The larger contact area for the VRC01 light chain may account for the ability of VRC01, but not NIH45-46, to neutralize the clade C CAP45.2.00.G3 strain, given that the NIH45-46 heavy chain paired with the VRC01 light chain neutralizes this strain, whereas the VRC01 heavy chain paired with the NIH45-46 light chain does not (Table S10 ). However, the VRC01 light chain did not increase the potency of NIH45-46 against three other viral strains (Fig. S5C) , suggesting that the Tyr28 interaction with gp120 carbohydrate is not obligatory.
Figure S1
Fig. S1. Sequence alignment of NIH45-46 and VRC01 (residue are numbered as defined for VRC01 (8)). Circles mark NIH45-46 residues that contact gp120; unfilled circles indicate side chain contacts, red circles indicate main chain contacts, and blue circles indicate contacts with both the side and the main chain. Black arrows indicate the boundaries of complementarity determining regions (CDRs) as defined by IMGT (43) , and residues within CDR loops as defined by the structure are marked with colors corresponding to the CDR colors in Fig. 1B . The locations of framework regions (FWRs) are indicated before, after, and between the CDRs. The definition of CDR2 in ref. (8) was the same as that defined by IMGT; however CDR2 was defined differently in refs. (25, 26) to include C-terminal residues within the C" β-strand and FWR3. . NIH45-46 contact surfaces that were mutated in RSC3. 93TH057 gp120 is shown using a ribbon diagram and color coded as in Fig. 1B . Residues at each contact interface are highlighted on the gp120 structure as a surface enclosing the contact residues. The surface area on the inner domain that is buried by contact with NIH45-46 is shown in pink with inner domain/bridging sheet residues that were mutated in RSC3 (8) 
FCTRGKYCT----YNWDFEHWGRGAP
Color-coded according to IC 50 values (μg/mL): red <0.1, orange 0.1-1, yellow 1-10, green 10-50, white > 50 (not neutralizing).
IC 50 values for VRC01 tested against the same viral strains are shown in Fig. S5C . Table S4 . Buried surface areas were calculated using Areaimol in CCP4 (44) . Color coding indicates the percent of the total buried surface area for each molecule. The insertion in CDRH3 contributes to a higher total buried surface area between the NIH45-46 heavy chain and gp120 compared with VRC01 (2241 Å 2 versus 1774 Å 2 total buried surface area; 1144 Å 2 versus 892 Å 2 buried surface area on the heavy chain). The difference in heavy chain buried area is largely due to more extensive gp120 contacts of the CDRH3 NIH45-46 loop: 326 Å 2 of surface area of the NIH45-46 CDRH3 are buried by contacting gp120, compared with 117 Å 2 for the VRC01 CDRH3. The extra contacts with gp120 created by the CDRH3 insertion allow the NIH45-46 footprint on gp120 to more closely resemble the CD4 footprint on gp120 than does the VRC01 footprint (Fig. 3C) . In particular, CD4 makes at least 1/3 of its contacts with the inner domain and bridging sheet of gp120, as opposed to only 13% of the total surface area contacted by VRC01 involving non-outer domain elements of gp120 (25) . The contact area with the inner domain and bridging sheet is increased to 25% in the NIH45-46 footprint on gp120. The largest difference between sensitivity to NIH45-46 and sensitivity to VRC01 was in strain 3016.v5.c45 (IC 50 s of >30 and 0.16 µg/mL, respectively). The most notable residue in 3016.v5.c45 is Tyr282 in loop D. This large residue may alter the conformation of loop D, which is closely contacted by the four-residue insertion in the NIH45-46 CDRH3. The absence of the insertion may permit VRC01 to better accommodate an altered loop D. The next largest NIH45-46/VRC01 difference, for strain C2101.c1 (12.78 vs. 0.36 µg/mL), may similarly relate to the unusual Lys99 gp120 residue replacing the asparagine that favorably interacts with Arg99b in the NIH45-46-gp120 crystal structure. Exclude >50 (μg/mL) % viruses <50 (μg/mL) 70% 65% 67% 52% 60% 50% 72% 52% 40% 33% 16% 22% 55% 57% 56% 38% 78% 92% 88% 75% Table S9 . Potencies of currently-available bNAbs. (A) Comparison of mean and median IC 50 (µg/mL) values for PGT antibodies and VRC01. A direct comparison between NIH45-46 and the PGT antibodies is not available. However VRC01 (which was shown in a direct comparison to be less potent than NIH45-46 (16)) was directly compared to the PGT antibodies using the same virus panel (18) and thus can serve as a reference for comparing NIH45-46 to the PGT antibodies. Mean IC 50 values were calculated using data taken from ref. (18) . Geometric and arithmetic means were calculated to include data for all viral strains (listed as Include >50, in which case, values reported as IC 50 >50 µg/mL were entered as 50 µg/mL in the calculation) and to exclude viral strains in which the IC 50 was >50 µg/mL (listed as Exclude >50, in which case the percent of viral strains with IC 50 s < 50 µg/mL is also reported). Mean IC 50 s are compared with the median IC 50 s as reported in ref. (18) . The table is color-coded according to IC 50 values (µg/mL): red <0.1, orange 0.1-1, yellow 1-10, green 10-50, white >50 (not neutralizing) or the percent of viral strains neutralized: red >90, orange 80-90, yellow 70-80, green 50-70, white <50.
